HeiLongJiang ZBD Pharmaceutical Co., Ltd. Class A

HeiLongJiang ZBD Pharmaceutical Co., Ltd. Class A

SSSE:603567
4.50
CNY
-0.16
(-3.43%)
-1.57EPS
4.95BMarket Cap
Apr 26Next Earn

Total Valuation

CNY

As of September 30, 2026, HeiLongJiang ZBD Pharmaceutical Co., Ltd. Class A carries a market capitalization of 4.95B, placing it among publicly traded companies globally. Its enterprise value stands at 8.07B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap4.95B
Enterprise Value8.07B

Important Dates

HeiLongJiang ZBD Pharmaceutical Co., Ltd. Class A's next confirmed earnings release is scheduled for April 26, 2027.

Earnings Date4/26/2027

Share Statistics

As of September 30, 2026, HeiLongJiang ZBD Pharmaceutical Co., Ltd. Class A has 940.24M shares outstanding.

Shares Outstanding940.24M

Valuation Ratios

These figures are as of September 30, 2026. The price-to-sales ratio is 17.26, and the price-to-book ratio stands at 0.85.

PS Ratio17.26
PB Ratio0.85
P/TBV Ratio1.09

Enterprise Valuation

These figures are as of September 30, 2026. The EV/Sales ratio of 28.15 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 8.07B versus a market cap of 4.95B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales28.15

Financial Position

As of September 30, 2026, HeiLongJiang ZBD Pharmaceutical Co., Ltd. Class A maintains a current ratio of 1.16, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 53.82, indicating elevated leverage, while an interest coverage ratio of -17.14 demonstrates limited ability to service its debt obligations.

Current Ratio1.16
Quick Ratio0.02
Debt / Equity53.82
Debt / EBITDA-1.85
Interest Coverage-17.14

Financial Efficiency

CNY

Over the twelve months ended September 30, 2026, HeiLongJiang ZBD Pharmaceutical Co., Ltd. Class A posted a negative return on equity (ROE) of -21.83, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -13.23, reflecting losses generated across the asset base. The company generates approximately 146,097.51 in revenue per employee across its workforce of 1,961.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.42 indicates how many times HeiLongJiang ZBD Pharmaceutical Co., Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)-21.83
Return on Assets (ROA)-13.23
Revenue Per Employee146,097.51
Employee Count1,961.00
Inventory Turnover0.42

Taxes

CNY

Over the twelve months ended September 30, 2026, HeiLongJiang ZBD Pharmaceutical Co., Ltd. Class A recorded an income tax benefit of -255.12M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -1.73B and -1.48B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax-255.12M

Stock Price Statistics

CNY

As of the close on November 17, 2026, HeiLongJiang ZBD Pharmaceutical Co., Ltd. Class A's stock has declined approximately 60.00% over the past 52 weeks. The 50-day moving average sits at 5.13, while the 200-day moving average is 6.37.

52-Week Price Change-60.00%
50-Day Moving Average5.13
200-Day Moving Average6.37

Income Statement

CNY

Over the twelve months ended September 30, 2026, HeiLongJiang ZBD Pharmaceutical Co., Ltd. Class A generated 286.50M in revenue and converted that into -1.48B in net income, yielding earnings per share of -1.57. EBITDA reached -1.70B, while operating income came in at -651.47M.

Revenue286.50M
Gross Profit-335.73M
Operating Income-651.47M
Pretax Income-1.73B
Net Income-1.48B
EBITDA-1.70B
EBIT-1.70B
Earnings Per Share (EPS)-1.57

Balance Sheet

CNY

As of September 30, 2026, HeiLongJiang ZBD Pharmaceutical Co., Ltd. Class A holds 60.35M in cash and equivalents against 3.14B in total debt, resulting in a net debt position of 1.81B. Total book value stands at 5.80B, with working capital of 614.19M providing operational flexibility.

Cash & Cash Equivalents60.35M
Total Debt3.14B
Net Debt1.81B
Equity (Book Value)5.80B
Book Value Per Share6.17
Working Capital614.19M

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-30.15M

Margins

Over the twelve months ended September 30, 2026, HeiLongJiang ZBD Pharmaceutical Co., Ltd. Class A posted a gross margin of -117.18, reflecting its pricing power and cost economics. The operating margin of -227.39 and net profit margin of -515.13 provide insight into operational efficiency.

Gross Margin-117.18
Operating Margin-227.39
Pretax Margin-604.30
Profit Margin-515.13
EBITDA Margin-593.98

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, HeiLongJiang ZBD Pharmaceutical Co., Ltd. Class A paid dividends of 0.10 per share. The dividend payout ratio of -6.62 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 7.22, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to HeiLongJiang ZBD Pharmaceutical Co., Ltd. Class A shareholders.

Dividend Per Share0.10
Payout Ratio-6.62
Shareholder Yield7.22

Stock Splits

HeiLongJiang ZBD Pharmaceutical Co., Ltd. Class A's most recent stock split took place on June 13, 2016 with a 1:2 split ratio.

Last Split Date6/13/2016
Split Ratio1:2

Scores

As of September 30, 2026, HeiLongJiang ZBD Pharmaceutical Co., Ltd. Class A has an Altman Z-Score of 0.92, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score0.92